Hormonal IUD (Mirena/Kyleena) in Your 60s and Beyond

Why Would a Woman in Her 60s Still Have or Want a Hormonal IUD?

By your 60s, contraception is almost certainly off the table. Menopause, defined as 12 consecutive months without a menstrual period, ends natural fertility permanently. Yet a significant number of women arrive at their 60s with a Mirena already in place, or their clinician proposes one as part of a hormone therapy plan. Both situations are worth understanding clearly.

The levonorgestrel intrauterine device (LNG-IUD) has two commercially available versions in the United States. Mirena carries 52 mg of levonorgestrel and is FDA-approved for up to 8 years of use for contraception and up to 5 years for heavy menstrual bleeding. Kyleena carries 19.5 mg and is approved for up to 5 years for contraception. Neither device is FDA-approved specifically for endometrial protection during menopausal hormone therapy (MHT), but that off-label use is well-established in clinical practice and supported by professional society guidance.

The Endometrial Protection Rationale

When a postmenopausal woman takes systemic estrogen, the uterine lining responds by thickening. Unopposed estrogen, meaning estrogen without a progestogen to balance it, raises endometrial cancer risk substantially, which is why any woman with a uterus who uses systemic estrogen needs progestogen coverage. Traditionally that meant an oral or transdermal progestin. The LNG-IUD delivers progestin directly to the endometrium, keeping systemic absorption low while still protecting the lining. This is a meaningful advantage for women who experience mood changes, bloating, or breast tenderness from systemic progestins.

The Convenience Factor

If you had a Mirena inserted in your mid-to-late 50s for heavy perimenopausal bleeding and you are now post-menopause and using estrogen therapy, that device may still be doing exactly what you need. Removing it and switching to oral or transdermal progestin is an option, but it is not automatically the better one.

Hormonal Status in Your 60s: What Changes the Calculation

At 60, virtually all women are post-menopause. The average age of natural menopause in the United States is 51.4 years, which means most women in their 60s crossed that threshold nearly a decade ago. Estrogen and progesterone production from the ovaries has ceased. FSH is persistently elevated. The hormonal environment is fundamentally different from the perimenopausal years when the IUD may have been inserted.

How This Affects Levonorgestrel Release

The LNG-IUD releases hormone at a rate that declines over its approved lifespan. Mirena starts at roughly 20 mcg/day and drops to approximately 10 mcg/day by year five. Even at its initial rate, the systemic levonorgestrel exposure is far lower than an oral contraceptive pill. In postmenopausal women not taking systemic estrogen, those small systemic levels have minimal clinical effect on hot flashes, bone density, or cardiovascular markers, because the dose is designed for local endometrial action, not systemic hormone replacement.

No Estrogen From the Device

A point that surprises many women: the LNG-IUD contains no estrogen. It will not treat hot flashes, vaginal dryness, or bone loss. If you are relying on the device alone to manage menopause symptoms, it will not do that job. Any menopausal symptom relief requires a separate estrogen prescription.

Fertility Is Gone, But the IUD Is Not Automatically Unnecessary

The ACOG Practice Bulletin on Intrauterine Devices notes that IUDs have noncontraceptive benefits that extend beyond reproductive years. For postmenopausal women on MHT, this is the primary remaining clinical reason to keep or insert one.

The Evidence for LNG-IUD as Endometrial Protection in Menopause

Clinicians have used the LNG-IUD as the progestogen arm of MHT for decades in Europe, and the evidence base, while not as large as that for oral progestins, is genuinely reassuring. Here is how to think about the data.

What the Trials Show

A 2018 systematic review published in Climacteric found that the 52 mg LNG-IUD provided endometrial protection equivalent to oral progestogens when used alongside systemic estrogen in peri- and post-menopausal women, with endometrial atrophy or an inactive pattern seen in the large majority of biopsies. The rate of endometrial hyperplasia was below 1% across the reviewed studies, a benchmark consistent with standard oral progestin regimens.

The Women's Health Initiative (WHI) studied oral conjugated equine estrogen plus medroxyprogesterone acetate, not an LNG-IUD, so that trial's cardiovascular and breast cancer findings do not directly translate to the IUD-plus-estrogen combination. Women should understand this distinction clearly rather than assuming all progestogen delivery methods carry identical risks. The systemic progestin exposure from the LNG-IUD is orders of magnitude lower than from the WHI oral regimen.

Breast Cancer Considerations

The relationship between progestogens and breast cancer risk is one of the most actively debated areas in women's health. A 2019 observational study in the BMJ found that all forms of hormone therapy, including local-delivery progestins, were associated with some increase in breast cancer risk compared to no MHT, though absolute risks varied by formulation and duration. The LNG-IUD was associated with lower absolute risk than combined oral MHT in that analysis. Women with a personal or strong family history of hormone-receptor-positive breast cancer should discuss this specifically with their oncologist or gynecologist before using any progestogen-containing device.

The MHT Regimen That Pairs With the IUD

Clinicians typically use the LNG-IUD as the progestogen component in a continuous-combined or long-cycle regimen alongside transdermal or oral estradiol. The Menopause Society's 2023 position statement on hormone therapy recognizes the LNG-IUD as a valid progestogen delivery method for women with a uterus using systemic estrogen, while noting the evidence base is smaller than for oral preparations.

Practical Considerations for Women in Their 60s

Insertion After Menopause: Pain and Perforation Risk

If you have never had an IUD and your clinician is proposing one now, insertion after menopause is more uncomfortable and carries a somewhat higher perforation risk than insertion during reproductive years. The postmenopausal cervix is less flexible. Estrogen-depleted tissue is more fragile. Uterine perforation rates at insertion are estimated at 0.5 to 2.0 per 1,000 insertions overall, and postmenopausal status is a recognized risk factor for the higher end of that range.

Options to reduce procedural discomfort include:

• Vaginal misoprostol 400 mcg placed 3 to 12 hours before insertion (evidence for benefit in postmenopausal women is mixed but some clinicians still use it)
• Topical or intracervical lidocaine
• Scheduling the procedure with a clinician experienced in postmenopausal insertions
• A short course of vaginal estrogen in the weeks before insertion to improve tissue quality

Bleeding Patterns

Postmenopausal women with an LNG-IUD often experience no bleeding at all, which is expected and reassuring. Any new vaginal bleeding in a postmenopausal woman requires evaluation regardless of IUD status. The device does not mask endometrial pathology, but any bleeding should prompt an endometrial assessment to rule out hyperplasia or malignancy, because postmenopausal bleeding is never assumed to be device-related without investigation.

Strings and Monitoring

Postmenopausal vaginal atrophy can make the IUD strings less accessible at routine check. Your clinician should confirm string position at each annual visit. If strings are not visible, an ultrasound confirms the device is correctly placed. A lost string in a postmenopausal woman does not mean the IUD has migrated, but it does need to be documented.

Who This Device Is Right For in Your 60s

Good Candidates

• Women in their early 60s who transitioned to post-menopause with a Mirena already in place and are now starting or continuing systemic estrogen therapy
• Women who had significant side effects from oral or transdermal progestins (mood changes, bloating, breast tenderness) and want localized progestin delivery
• Women with a history of heavy perimenopausal bleeding who found the IUD managed their symptoms well and are now using it as their progestogen arm on MHT
• Women who want the lowest systemic progestin exposure possible while still protecting their endometrium

Not the Right Choice For

• Women who are fully post-menopause, not taking systemic estrogen, and have no other clinical reason for the device. Leaving an expired device in place beyond its approved duration is not recommended, and inserting a new one without a clear indication adds procedural risk without benefit.
• Women with a history of hormone-receptor-positive breast cancer, unless specifically cleared by their oncology team
• Women with unexplained postmenopausal bleeding that has not yet been fully evaluated
• Women with a uterine cavity that cannot accommodate the device (fibroid distortion, cervical stenosis)
• Women with current or recent pelvic inflammatory disease or a sexually transmitted infection

Pregnancy, Lactation, and Contraception: Required Clinical Information

Pregnancy

Pregnancy is not a realistic concern for a confirmed postmenopausal woman. Spontaneous conception after true menopause is not physiologically possible. The LNG-IUD is, however, contraindicated in known or suspected pregnancy. This contraindication is clinically irrelevant in your 60s given the absence of ovarian function, but it is listed in every prescribing information document. If a device were to be inserted in a woman who turned out to have an unrecognized early pregnancy (a scenario essentially impossible after confirmed menopause but theoretically possible in the rare perimenopausal woman in her early 60s still having infrequent cycles), it would require prompt removal and obstetric evaluation.

For any woman who is not yet certain she has reached menopause (confirmed by 12 consecutive period-free months, or by FSH levels above 30 IU/L on two readings taken weeks apart), the LNG-IUD still provides excellent contraception. The failure rate of the 52 mg LNG-IUD is less than 0.1% per year, making it one of the most effective reversible methods available.

Lactation

Not applicable at this life stage.

Contraception After Menopause

None needed. ACOG recommends that women can discontinue contraception after 12 consecutive months without a menstrual period in women over 50. If you reach confirmed menopause with an IUD in place, the device may be removed at your next scheduled visit or kept if it serves another clinical purpose (endometrial protection during MHT).

When to Remove the IUD

Device Has Reached the End of Its Approved Lifespan

Mirena is approved for 8 years for contraception. Kyleena is approved for 5 years. A device kept beyond these durations has not been tested for continued efficacy and cannot be assumed to still deliver adequate hormone for endometrial protection. Removal and replacement, or a switch to an alternative progestogen, is appropriate at expiration.

You Are Stopping Estrogen Therapy

If you decide to discontinue MHT, the rationale for the IUD as endometrial protection disappears. There is no clinical reason to maintain a progestin-releasing device without systemic estrogen in a postmenopausal woman, unless symptom management or some other specific indication applies.

You Develop Breast Cancer

Women diagnosed with hormone-receptor-positive breast cancer will likely be advised by their oncologist to stop all exogenous hormones. Even the low systemic levonorgestrel from the IUD may warrant removal, depending on the receptor status and treatment plan. This decision should involve both the oncologist and the gynecologist.

Practical Removal Notes

Removal in a postmenopausal woman may be more difficult than insertion. Cervical atrophy can make the os narrow. Your clinician may recommend a short course of vaginal estrogen before the removal appointment to soften cervical tissue. Most removals are completed in the office without anesthesia, but knowing this in advance helps you prepare.

Sex-Specific Physiology: What Makes This Different for Older Women

Levonorgestrel is a synthetic progestin that binds the progesterone receptor with high affinity. It also has weak androgenic activity. In premenopausal women, this can occasionally manifest as acne or changes in libido, but in postmenopausal women using the IUD, systemic levels are so low (typically below 150 pg/mL for Mirena users) that androgenic side effects are rarely reported.

Postmenopausal women show slightly lower systemic LNG levels from the same device than premenopausal women, likely because the postmenopausal uterus absorbs hormone differently and there is no competing endogenous progesterone to displace LNG from binding proteins. The clinical significance is that the endometrial effect may actually be well-maintained even at lower systemic levels, which is reassuring for the protective indication.

Genitourinary syndrome of menopause (GSM), the constellation of vaginal dryness, atrophy, and dyspareunia that affects up to 50% of postmenopausal women, is not treated by the LNG-IUD. Women should not expect any improvement in vaginal dryness, discomfort with intercourse, or urinary symptoms from the device. Local vaginal estrogen remains the evidence-based first line for GSM and can be used safely alongside the IUD.

A Note on the Evidence Gap

Women over 60 are systematically underrepresented in IUD trials. Most of the data on LNG-IUD safety and efficacy comes from women of reproductive age. The endometrial protection data is largely from peri- and early postmenopausal women in their 50s, with very limited data from women aged 65 and older. The extrapolation to this age group is clinically reasonable, but it is an extrapolation. The Menopause Society acknowledges this evidence gap and calls for larger, longer studies in older postmenopausal women on MHT. Your clinician should be transparent about this when discussing the decision with you.

"The levonorgestrel IUD is a clinically rational choice for endometrial protection in older women on estrogen therapy, but we are working with a thinner evidence base than we would like," says Rachel Goldberg, MD, WomanRx editorial board member and board-certified OB-GYN. "The device's low systemic progestin profile is a genuine advantage for women who struggled with mood or metabolic side effects from oral progestins, and that advantage does not disappear after menopause."

Bone Health and Cardiovascular Considerations

Older women appropriately think about bone density and heart health alongside any hormonal decision.

Bone

The LNG-IUD alone has no established benefit for bone density. Estrogen is the driver of bone-protective effects in MHT. Postmenopausal women have a 50% lifetime risk of an osteoporotic fracture, and the decision to use MHT is partly driven by whether that protective benefit applies to an individual woman's fracture risk. The progestogen component, whether oral or from an IUD, does not significantly add to or subtract from estrogen's skeletal effects at the doses used in MHT.

Cardiovascular

Systemic progestins, particularly medroxyprogesterone acetate, may blunt some of estrogen's favorable lipid effects. Because the LNG-IUD delivers negligible systemic progestin, it may have a more favorable cardiovascular profile than oral combined MHT. Direct trial data in women over 60 specifically using the IUD-plus-estrogen regimen for cardiovascular endpoints is limited. This is an area where the evidence gap applies directly.